N. Klesel

717 total citations
36 papers, 604 citations indexed

About

N. Klesel is a scholar working on Pharmacology, Molecular Medicine and Molecular Biology. According to data from OpenAlex, N. Klesel has authored 36 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pharmacology, 18 papers in Molecular Medicine and 14 papers in Molecular Biology. Recurrent topics in N. Klesel's work include Antibiotics Pharmacokinetics and Efficacy (27 papers), Antibiotic Resistance in Bacteria (18 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (9 papers). N. Klesel is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (27 papers), Antibiotic Resistance in Bacteria (18 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (9 papers). N. Klesel collaborates with scholars based in Germany, India and France. N. Klesel's co-authors include M. Limbert, Gerhard Seibert, E. Schrinner, K. Seeger, A. Markus, Irvin Winkler, J. BLUMBACH, B. N. GANGULI, Rajendrakumar H. Jani and Péter Hajdú and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Virology and Journal of Antimicrobial Chemotherapy.

In The Last Decade

N. Klesel

35 papers receiving 533 citations

Peers

N. Klesel

PHARM

EPIDE

MICRO

M. Limbert Germany

J. F. Desnottes France

E. Schrinner Germany

F. Leitner United States

E. L. Moss United States

T. A. Pursiano United States

KANJI TSUCHIYA Japan

Axel Dalhoff Germany

P. Acred United Kingdom

M. J. Bywater United Kingdom

M. Limbert Germany

N. Klesel

464 ×1.3

PHARM

298 ×1.4

229 ×1.4

146 ×1.2

EPIDE

99 ×1.0

MICRO

Citations per year, relative to N. Klesel N. Klesel (= 1×) peers M. Limbert

Countries citing papers authored by N. Klesel

Since Specialization

Citations

This map shows the geographic impact of N. Klesel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Klesel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Klesel more than expected).

Fields of papers citing papers by N. Klesel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Klesel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Klesel. The network helps show where N. Klesel may publish in the future.

Co-authorship network of co-authors of N. Klesel

This figure shows the co-authorship network connecting the top 25 collaborators of N. Klesel. A scholar is included among the top collaborators of N. Klesel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Klesel. N. Klesel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klesel, N., et al.. (1995). Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. Journal of Antimicrobial Chemotherapy. 35(6). 805–819. 25 indexed citations

Klesel, N., M. Limbert, A. Markus, et al.. (1995). Activity of Levofloxacin, Ofloxacin, D-Ofloxacin and Ciprofloxacin against Systemic and Respiratory Tract Infections in Laboratory Animals. Drugs. 49(Supplement 2). 211–214. 1 indexed citations

Jani, Rajendrakumar H., J. BLUMBACH, B. N. GANGULI, et al.. (1992). Mersacidin, a new antibiotic from Bacillus In vitro and in vivo antibacterial activity.. The Journal of Antibiotics. 45(6). 839–845. 110 indexed citations

Klesel, N., et al.. (1992). Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs. Journal of Antimicrobial Chemotherapy. 29(suppl A). 31–37. 15 indexed citations

Seibert, Gerhard, et al.. (1992). The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 29(suppl A). 25–30. 25 indexed citations

Limbert, M., Gerhard Seibert, Irvin Winkler, et al.. (1992). Antibacterial activity in vitro of cefpirome against clinical isolates causing sexually transmitted diseases. Journal of Antimicrobial Chemotherapy. 29(suppl A). 13–17. 4 indexed citations

Klesel, N., et al.. (1992). RU 29 246, the active compound of the cephalosporin prodrug-ester HR 916. III. Pharmacokinetic properties and antibacterial activity in vivo.. The Journal of Antibiotics. 45(6). 922–931. 3 indexed citations

Bauernfeind, A., R. Jungwirth, N. Klesel, et al.. (1992). RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.. The Journal of Antibiotics. 45(4). 505–520. 12 indexed citations

Markus, A., N. Klesel, M. Limbert, et al.. (1992). RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. II. Stability to .BETA.-lactamases and affinity for penicillin-binding proteins.. The Journal of Antibiotics. 45(4). 521–526. 2 indexed citations

10.

Klesel, N., et al.. (1990). Comparative chemotherapeutic activity of cefpirome and imipenem in experimental infections.. The Journal of Antibiotics. 43(1). 100–106. 5 indexed citations

11.

Klesel, N., et al.. (1989). Synergistic antibacterial activity of cefotaxime and the penem HRE 664 in an improved in vitro model simulating serum and tissue pharmacokinetics.. PubMed. 1(4 Suppl). 479–81. 1 indexed citations

12.

Lattrell, Rudolf, J. BLUMBACH, Klaus Fleischmann, et al.. (1988). Synthesis and structure-activity relationships in the cefpirome series. II. Analogues of cefpirome with different 7-heteroarylacetamido and 3'-ammonium substituents.. The Journal of Antibiotics. 41(10). 1395–1408. 8 indexed citations

13.

Uihlein, M., N. Klesel, & K. Seeger. (1988). Determination of cefpirome (HR 810) in serum and urine. Infection. 16(2). 135–140. 13 indexed citations

14.

Klesel, N., et al.. (1987). HRE 664, a new parenteral penem. II. Evaluation of the pharmacokinetic behavior and the chemotherapeutic activity in animals.. The Journal of Antibiotics. 40(8). 1184–1192. 4 indexed citations

15.

Körting, Hans Christian, et al.. (1987). Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrobial Agents and Chemotherapy. 31(11). 1822–1825. 10 indexed citations

16.

Verho, M., et al.. (1987). Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate. Infection. 15(3). 202–206. 11 indexed citations

17.

Klesel, N., M. Limbert, Gerhard Seibert, Irvin Winkler, & E. Schrinner. (1986). Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice. Infection. 14(S1). S36–S39. 7 indexed citations

18.

Klesel, N., M. Limbert, K. Seeger, et al.. (1984). Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals.. The Journal of Antibiotics. 37(8). 901–909. 21 indexed citations

19.

Klesel, N., M. Limbert, Gerhard Seibert, Irvin Winkler, & E. Schrinner. (1984). Cefodizime, an aminothiazolyl cephalosporin. III. Therapeutic activity against experimentally induced pneumonia in mice.. The Journal of Antibiotics. 37(12). 1712–1718. 21 indexed citations

20.

Klesel, N. & K. Seeger. (1983). Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals. Infection. 11(6). 318–321. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact